The United States release date for atomoxetine, marketed as Strattera, was March 24, 2006 [1]. This date marks its approval by the U.S. Food and Drug Administration (FDA) [1].
When Did Strattera First Become Available?
Strattera (atomoxetine) became available in the U.S. shortly after its FDA approval on March 24, 2006 [1].
How Long Does Atomoxetine Patent Protection Last?
Information regarding the specific patent expiry dates for atomoxetine is available through resources like DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which is crucial for understanding market exclusivity and the potential for generic competition [2].
Who Makes Atomoxetine?
Atomoxetine was originally developed and marketed by Eli Lilly and Company under the brand name Strattera [1]. Following patent expirations, generic versions of atomoxetine may be manufactured by various pharmaceutical companies.
What Is Atomoxetine Used For?
Atomoxetine is a medication used to treat attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults [1]. It is a selective norepinephrine reuptake inhibitor [1].